Leveraging Organoids to Address Neurodegenerative Diseases

OrganoTherapeutics

Apr 29, 2021PAO-04-22-R221-66-400

Neurology Organoids The Road to 2021 PA TV (video)

During the Road to 2021 trip, Dr. Jens Schwamborn, Co-Founder of OrganoTherapeutics, discusses the exploration of Parkinson’s disease using brain organoids.

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

PAO-06-26-CL-04Jul 1, 2026

DBS

Advancing Deep Brain Stimulation Through Better Targeting and Smarter Devices

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-06-26-PA-23Jun 26, 2026

Organoids

Building Bioreactors for Living Architecture: The Manufacturing Challenge for Clinical-Grade Organoids

David Alvaro, Ph.D.

Pharma's Almanac

PAO-05-26-PA-25Jun 22, 2026

CNS Clinical

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969

Insilico Medicine

PR-06-26-01Jun 17, 2026

Protein Misfolding

Protein Misfolding as a Therapeutic Axis in Neurodegenerative Disease

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-08Jun 15, 2026

Alzheimer Therapies

Beyond Amyloid: Building the Next Alzheimer’s Disease Therapeutic Ecosystem

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-05Jun 10, 2026

Neurology

Next-Generation Therapies for Neurological Diseases

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-04-26-PA-18Apr 24, 2026

Neuro RNA

Targeting RNA in the Nervous System: The Rise of Antisense and RNA Therapeutics

David Alvaro, Ph.D.

Pharma's Almanac

PAO-04-26-PA-09Apr 15, 2026

Neuro Biomarkers

Precision Neurology: How Biomarkers Are Redefining Clinical Trial Design

David Alvaro, Ph.D.

Pharma's Almanac

PAO-04-26-PA-08Apr 13, 2026

Neuro CMC

Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics

David Alvaro, Ph.D.

Pharma's Almanac

PAO-04-26-PA-03Apr 3, 2026

BBB

Opening the Blood–Brain Barrier: Device-Based Strategies for CNS Drug Delivery

David Alvaro, Ph.D.

Pharma's Almanac

PAO-04-26-PA-02Apr 2, 2026

BBB

Engineering Biologics and Nanomedicines to Traverse the Blood–Brain Barrier

David Alvaro, Ph.D.

Pharma's Almanac

PAO-04-26-PA-01Apr 1, 2026

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us Nice Insight That's Nice

Reach Our Team

My Account

Subscribe for the newsletter

Subscribe for the Newsletter

Mobile Navigation

Leveraging Organoids to Address Neurodegenerative Diseases

Related Content

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

DBS

Advancing Deep Brain Stimulation Through Better Targeting and Smarter Devices

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Organoids

Building Bioreactors for Living Architecture: The Manufacturing Challenge for Clinical-Grade Organoids

David Alvaro, Ph.D.

Pharma's Almanac

CNS Clinical

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969

Insilico Medicine

Protein Misfolding

Protein Misfolding as a Therapeutic Axis in Neurodegenerative Disease

David Alvaro, Ph.D.

Pharma's Almanac

Alzheimer Therapies

Beyond Amyloid: Building the Next Alzheimer’s Disease Therapeutic Ecosystem

David Alvaro, Ph.D.

Pharma's Almanac

Neurology

Next-Generation Therapies for Neurological Diseases

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Neuro RNA

Targeting RNA in the Nervous System: The Rise of Antisense and RNA Therapeutics

David Alvaro, Ph.D.

Pharma's Almanac

Neuro Biomarkers

Precision Neurology: How Biomarkers Are Redefining Clinical Trial Design

David Alvaro, Ph.D.

Pharma's Almanac

Neuro CMC

Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics

David Alvaro, Ph.D.

Pharma's Almanac

BBB

Opening the Blood–Brain Barrier: Device-Based Strategies for CNS Drug Delivery

David Alvaro, Ph.D.

Pharma's Almanac

BBB

Engineering Biologics and Nanomedicines to Traverse the Blood–Brain Barrier

David Alvaro, Ph.D.

Pharma's Almanac

Related Content

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

DBS

Advancing Deep Brain Stimulation Through Better Targeting and Smarter Devices

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Organoids

Building Bioreactors for Living Architecture: The Manufacturing Challenge for Clinical-Grade Organoids

David Alvaro, Ph.D.

Pharma's Almanac

CNS Clinical

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969

Insilico Medicine

Protein Misfolding

Protein Misfolding as a Therapeutic Axis in Neurodegenerative Disease

David Alvaro, Ph.D.

Pharma's Almanac

Alzheimer Therapies

Beyond Amyloid: Building the Next Alzheimer’s Disease Therapeutic Ecosystem

David Alvaro, Ph.D.

Pharma's Almanac

Neurology

Next-Generation Therapies for Neurological Diseases

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Neuro RNA